Showing 2851-2860 of 3315 results for "".
- Zubisoft Launches New Nomogram and Laser Treatment Planner for Zeiss SMILEhttps://modernod.com/news/zubisoft-launches-new-nomogram-and-laser-treatment-planner-for-zeiss-smile/2478920/Swiss-based Zubisoft has developed the IBRA nomogram calculator, designed to allow refractive surgeons to optimize treatment planning for small incision lenticular extraction with the Zeiss VisuMax femto laser platfor
- Remembering Ophthalmic Industry Executive George Marcellinohttps://modernod.com/news/remembering-george-marcellino-vice-president-of-marketing-and-clinical-affairs/2478916/Ophthalmic industry executive George Marcellino, PhD, whose work lead to the development of several new technologies and medical devices, died on February 10, 2021. Most recently, Dr. Marcellino served as vice president of clinical affairs and marketing at Iridex. On its website, Iridex posted th
- AcuFocus Submits US Premarket Approval Application to the FDA for Its IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-submits-us-premarket-approval-application-to-the-fda-for-its-ic-8-small-aperture-iol/2478903/AcuFocus announced that it has submitted a premarket approval (PMA) application to the FDA for its IC-8 small aperture IOL. The IC-8 IOL is an aspheric monofocal lens that features an embedded filter with a small central aperture. Using wavefront-filtering, small aperture optics, the lens is desi
- Re-Vana Therapeutics Names New Members to the Executive Teamhttps://modernod.com/news/re-vana-therapeutics-names-new-members-to-the-executive-team/2478897/Re-Vana Therapeutics announced the appointment of Michael Nash as Chief Commercial Officer and David Shima, PhD, as Vice President of Research and Development. The two executives will play critical leadership roles at Re-Vana as the company develops innovative sustained release therapies for a br
- UK Real-World Data Show COVID-19 Vaccine Linked to Lower Infection, Hospitalization Rateshttps://modernod.com/news/uk-real-world-data-show-covid-19-vaccine-linked-to-lower-infection-hospitalization-rates/2478899/Data from new analyses were released Monday shedding light on the short-term impacts of COVID-19 vaccinations in the UK. One analysis from Public Health England’s (PHE) SIREN study appears to corroborate early evidence that Pfizer and BioNTech’s vaccine BNT162b2 offers high levels of
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scriptshttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/Kala Pharmaceuticals announced that pharmacy benefit manager Express Scripts has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. Eysuvis is the first and only prescription therapy appr
- GenSight Biologics Announces Publication of Results from Lumevoq Phase 1/2a Clinical Trial REVEAL in BioDrugshttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/GenSight Biologics announced that the journal BioDrugs has published results from REVEAL, the phase 1/2a clinical trial that evaluated the safety of Lumevoq gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the ph
- Roche’s Actemra Reduces Deaths in Hospitalized COVID-19 Patients: Studyhttps://modernod.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/New findings released Thursday from the ongoing RECOVERY trial showed that Roche’s arthritis drug Actemra (tocilizumab) significantly reduced mortality among patients hospitalized with severe COVID-19, according to researchers leading the study at the University of Oxford. The intravenous I
- Oculus and Myopia Profile Aim to Increase Knowledge on Myopiahttps://modernod.com/news/oculus-and-myopia-profile-aim-to-increase-knowledge-on-myopia/2478860/Myopia Profile and Oculus have commenced a partnership to increase ECP knowledge and clinical confidence in measurement and interpretation of axial length in myopia. Specific educational content, research summaries and case studies will be developed, to be housed on MyopiaProfile.com and shared a